NME2 Antibody / NM23-H2

Western blot: 1-2ug/ml,Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT

Optimal dilution of the NME2 antibody should be determined by the researcher.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

The nm23 gene, a potential suppressor of metastasis, was originally identified by differential hybridization between two murine melanoma sub-lines, one with a high and the second with a low metastatic capacity. Highly metastatic sub-lines exhibit much lower levels of nm23 than less metastatic cells. Based on sequence analysis, nm23 appears highly related to nucleotide diphosphate kinases (NDP). In humans, NDP kinases A and B are identical to two isotypes of human nm23 homologs, namely nm23-H1 and H2, respectively. nm23-H2 is identical in sequence to PuF, a transcription factor that binds to nuclease hypersensitive elements at positions 142 to 115 of the human c-Myc promotor.

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide

Recombinant human protein was used as the immunogen for this NME2 antibody.

This NME2 antibody is available for research use only.

Cytoplasmic, nuclear

Yes

Protein G affinity chromatography

Human

P22392